APOBEC3A Inhibits Early HIV-1 Infection in Myeloid Cells
Author Information
Author(s): Gregory Berger, Stéphanie Durand, Guillaume Fargier, Xuan-Nhi Nguyen, Stéphanie Cordeil, Serge Bouaziz, Delphine Muriaux, Jean-Luc Darlix, André Cimarelli
Primary Institution: Department of Human Virology, ENS-L, Lyon, France
Hypothesis
Can APOBEC3A inhibit HIV-1 infection during the early phases in myeloid cells?
Conclusion
APOBEC3A acts as an antiviral factor that restricts HIV-1 infection specifically in myeloid cells during the early phases.
Supporting Evidence
- APOBEC3A is specifically expressed in myeloid cells.
- Silencing APOBEC3A increases susceptibility to HIV-1 infection in myeloid cells.
- APOBEC3A inhibits the accumulation of viral DNA during HIV-1 infection.
- Vpx from SIVSM/HIV-2 provides partial protection against APOBEC3A.
Takeaway
APOBEC3A is like a superhero for certain immune cells, helping them fight off HIV-1 before it can cause trouble.
Methodology
The study used ectopic expression and silencing of APOBEC3A in various myeloid cell types to assess its impact on HIV-1 infection.
Limitations
The study did not explore the effects of APOBEC3A in non-myeloid cells or in vivo.
Participant Demographics
The study involved human myeloid cells, including monocytes, macrophages, and dendritic cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website